Loading...
XSTO
INIT
Market cap21mUSD
Dec 04, Last price  
3.00SEK
1D
0.67%
1Q
-20.63%
IPO
-35.14%
Name

Initiator Pharma A/S

Chart & Performance

D1W1MN
XSTO:INIT chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
-70.63%
Rev. gr., 5y
%
Revenues
0k
Net income
-13k
L-43.46%
-892,000-8,582,000-10,298,000-8,288,000-8,697,000-21,064,000-38,455,000-22,872-12,932
CFO
-12m
L-31.55%
-178,000-7,784,000-13,582,000-8,553,000-8,064,000-34,097,000-32,701,000-17,648,000-12,080,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
IPO date
Mar 16, 2017
Employees
3
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT